Teva Launches Authorized Generic of Flector Patch in the United States.
M2 PHARMA-March 4, 2019-Teva Launches Authorized Generic of Flector Patch in the United States
(C)2019 M2 COMMUNICATIONS
- Israeli generic drugmaker Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) (TASE: TEVA) has launched an authorised generic of Flector1 Patch, 1.3%, in the US, the company said.
Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions.
With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US.
Currently, one in eight generic prescriptions dispensed in the US is filled with a Teva generic product.
With the launch of Diclofenac Epolamine Topical Patch, 1.3%, Teva now has over 16 medicines in the Analgesics and Antipyretics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) therapeutic area in the US
Flector Patch had annual sales of USD 123m in the US, according to IQVIA data as of December 2018.
Diclofenac Epolamine Topical Patch, 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Diclofenac Epolamine Topical Patch, 1.3% is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated for use on non-intact or damaged skin resulting from any etiology, including, exudative dermatitis, eczema, infected lesions, burns, or wounds.
Teva Pharmaceutical Industries is in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 4, 2019|
|Previous Article:||Pfizer Receives Positive CHMP Opinion for Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung...|
|Next Article:||PanTheryx Presents Positive Results from Two New DiaResQ Studies at its 2019 International Scientific Symposium.|